Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present)

被引：29

作者：

Zhang, Qian ^{[1
]}

Zheng, Pengwu ^{[1
]}

Zhu, Wufu ^{[1
]}

机构：

[1] Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang 330013, Jiangxi, Peoples R China

来源：

MOLECULES | 2020年 / 25卷 / 11期

基金：

中国国家自然科学基金;

关键词：

dual VEGFR; c-Met inhibitors; anticancer agents; research progress; C-MET; BIOLOGICAL EVALUATION; DUAL INHIBITORS; 4-PHENOXYQUINOLINE DERIVATIVES; DESIGN; DISCOVERY; RECEPTOR; MOIETY; PYRIDINE; IDENTIFICATION;

D O I：

10.3390/molecules25112666

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vascular endothelial growth factor receptor 2 (VEGFR-2) binds to VEGFR-A, VEGFR-C and VEGFR-D and participates in the formation of tumor blood vessels, mediates the proliferation of endothelial cells, enhances microvascular permeability, and blocks apoptosis. Blocking or downregulating the signal transduction of VEGFR is the main way to discover new drugs for many human angiogenesis-dependent malignancies. Mesenchymal epithelial transfer factor tyrosine kinase (c-Met) is a high affinity receptor for hepatocyte growth factor (HGF). Abnormal c-Met signaling plays an important role in the formation, invasion and metastasis of human tumors. Therefore, the HGF/c-Met signaling pathway has become a significant target for cancer treatment. Related studies have shown that the conduction of the VEGFR and c-Met signaling pathways has a synergistic effect in inducing angiogenesis and inhibiting tumor growth. In recent years, multi-target small molecule inhibitors have become a research hotspot, among which the research of VEGFR and c-Met dual-target small molecule inhibitors has become more and more extensive. In this review, we comprehensively summarize the chemical structures and biological characteristics of novel VEGFR/c-Met dual-target small-molecule inhibitors in the past five years.

引用

页数：21

共 75 条

[1] Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
Abdel-Mohsen, Heba T.
Omar, Mohamed A.
El Kerdawy, Ahmed M.
Mahmoud, Abeer E. E.
Ali, Mamdouh M.
El Diwani, Hoda I.
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 : 707 - 722
[2] Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors
Abdo, Nadia Y. Megally
Mohareb, Rafat Milad
Halim, Peter A.
[J]. BIOORGANIC CHEMISTRY, 2020, 97
[3] Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking
Ahmed, Eman M.
Khalil, Nadia A.
Taher, Azza T.
Refaey, Rana H.
Nissan, Yassin M.
[J]. BIOORGANIC CHEMISTRY, 2019, 92
[4] Current advances of targeting HGF/c-Met pathway in gastric cancer
Anestis, Aristomenis
Zoi, Ilianna
Karamouzis, Michalis V.
[J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (12)
[5] [Anonymous], 2012, ANN ONCOL, DOI [10.1016/S0923-7534(20)31988-8, DOI 10.1016/S0923-7534(20)31988-8]
[6] c-Met as a new marker of cellular senescence
Boichuck, Maria
Zorea, Jonathan
Elkabets, Moshe
Wolfson, Marina
Fraifeld, Vadim E.
[J]. AGING-US, 2019, 11 (09): : 2889 - 2897
[7] Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. Jean
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4427 - 4453
[8] Dejuan S., 2020, EURO J MED CHEM, DOI [10.1016/j.ejmech.2019.112025Get, DOI 10.1016/J.EJMECH.2019.112025GET]
[9] Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
Desai, Arpita
Small, Eric J.
[J]. FUTURE ONCOLOGY, 2019, 15 (20) : 2337 - 2348
[10] 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
Dokla, Eman M. E.
Fang, Chun-Sheng
Abouzid, Khaled A. M.
Chen, Ching S.
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182

← 1 2 3 4 5 6 7 8 →